A phase 1 / 2 randomized, blinded, placebo controlled study of Ipilimumab in combination with INCB024360 or placebo in unresectable or metastatic melanoma
Clinical Trial Grant
Awarded By
Incyte Corporation
Start Date
October 1, 2013
End Date
December 14, 2017
Awarded By
Incyte Corporation
Start Date
October 1, 2013
End Date
December 14, 2017